XMT-1535

XMT-1535 (also known as Rebmab200) is a humanized monoclonal antibody that specifically targets the Sodium-dependent phosphate transport protein 2B (NaPi2b), which is encoded by the SLC34A2 gene. It was developed as a humanized version of the murine MX35 antibody. NaPi2b is a lineage-specific marker expressed in several solid tumors, including epithelial ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma, as well as some normal tissues such as type II pneumocytes in the lung and fallopian tube epithelium. XMT-1535 is primarily utilized as the targeting moiety for the antibody-drug conjugate (ADC) XMT-1536 (Upifitamab rilsodotin), where it is conjugated to a cytotoxic auristatin payload via the Dolaflexin polymer platform. The antibody binds with high affinity to human NaPi2b and shows cross-reactivity with monkey, rat, and mouse versions of the protein.

Other names

MX35 humanized antibodyMX-35 humanized antibodyMX 35 humanized antibodyhumanized anti-NaPi2b antibody